File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination

TitleA novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination
Authors
Issue Date2009
PublisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.action
Citation
Plos One, 2009, v. 4 n. 1 How to Cite?
AbstractMucosal vaccination offers great advantage for inducing protective immune response to prevent viral transmission and dissemination. Here, we report our findings of a head-to-head comparison of two viral vectors modified vaccinia Ankara (MVA) and a novel replication-competent modified vaccinia Tian Tan (MVTT) for inducing neutralizing antibodies (Nabs) via intramuscular and mucosal vaccinations in mice. MVTT is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of Chinese people. The spike glycoprotein (5) of 5ARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two vectors to generate vaccine candidates MVTT-S and MVA-S. Using identical doses, MVTT-S induced lower levels (∼2-3-fold) of anti- SARS-CoV neutralizing antibodies (Nabs) than MVA-S through intramuscular inoculation. MVTT-S, however, was capable of inducing consistently 20-to-100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal or intraoral routes. These levels of MVTT-S-induced Nab responses were substantially (∼10-fold) higher than that induced via the intramuscular, route in the same experiments. Moreover, pre-exposure to the wild-type VTT via intranasal or intraoral route impaired the Nab response via the same routes of MVTT-S vaccination probably due to the pre-existing anti-VTT Nab response. The efficacy of intranasal or intraoral vaccination, however, was still 20-to-50-fold better than intramuscular inoculation despite the subcutaneous pre-exposure to wild-type VTT. Our data have implications for people who maintain low levels of anti-VTT Nabs after historical smallpox vaccination. MVTT is therefore an attractive live viral vector for mucosal vaccination. Copyright: © 2009 Huang et al.
Persistent Identifierhttp://hdl.handle.net/10722/60139
ISSN
2015 Impact Factor: 3.057
2015 SCImago Journal Rankings: 1.395
PubMed Central ID
ISI Accession Number ID
Funding AgencyGrant Number
National Basic Research Program of China2006CB504208
HK-RGC762208
University Development Fund of the University of Hong Kong to its AIDS Institute
Funding Information:

This work was supported by the National Basic Research Program of China (the 973 project 2006CB504208), HK-RGC 762208 and the University Development Fund of the University of Hong Kong to its AIDS Institute. Sponsors were not involved in the study.

References

 

DC FieldValueLanguage
dc.contributor.authorHuang, Xen_HK
dc.contributor.authorLu, Ben_HK
dc.contributor.authorYu, Wen_HK
dc.contributor.authorFang, Qen_HK
dc.contributor.authorLiu, Len_HK
dc.contributor.authorZhuang, Ken_HK
dc.contributor.authorShen, Ten_HK
dc.contributor.authorWang, Hen_HK
dc.contributor.authorTian, Pen_HK
dc.contributor.authorZhang, Len_HK
dc.contributor.authorChen, Zen_HK
dc.date.accessioned2010-05-31T04:04:32Z-
dc.date.available2010-05-31T04:04:32Z-
dc.date.issued2009en_HK
dc.identifier.citationPlos One, 2009, v. 4 n. 1en_HK
dc.identifier.issn1932-6203en_HK
dc.identifier.urihttp://hdl.handle.net/10722/60139-
dc.description.abstractMucosal vaccination offers great advantage for inducing protective immune response to prevent viral transmission and dissemination. Here, we report our findings of a head-to-head comparison of two viral vectors modified vaccinia Ankara (MVA) and a novel replication-competent modified vaccinia Tian Tan (MVTT) for inducing neutralizing antibodies (Nabs) via intramuscular and mucosal vaccinations in mice. MVTT is an attenuated variant of the wild-type VTT, which was historically used as a smallpox vaccine for millions of Chinese people. The spike glycoprotein (5) of 5ARS-CoV was used as the test antigen after the S gene was constructed in the identical genomic location of two vectors to generate vaccine candidates MVTT-S and MVA-S. Using identical doses, MVTT-S induced lower levels (∼2-3-fold) of anti- SARS-CoV neutralizing antibodies (Nabs) than MVA-S through intramuscular inoculation. MVTT-S, however, was capable of inducing consistently 20-to-100-fold higher levels of Nabs than MVA-S when inoculated via either intranasal or intraoral routes. These levels of MVTT-S-induced Nab responses were substantially (∼10-fold) higher than that induced via the intramuscular, route in the same experiments. Moreover, pre-exposure to the wild-type VTT via intranasal or intraoral route impaired the Nab response via the same routes of MVTT-S vaccination probably due to the pre-existing anti-VTT Nab response. The efficacy of intranasal or intraoral vaccination, however, was still 20-to-50-fold better than intramuscular inoculation despite the subcutaneous pre-exposure to wild-type VTT. Our data have implications for people who maintain low levels of anti-VTT Nabs after historical smallpox vaccination. MVTT is therefore an attractive live viral vector for mucosal vaccination. Copyright: © 2009 Huang et al.en_HK
dc.languageengen_HK
dc.publisherPublic Library of Science. The Journal's web site is located at http://www.plosone.org/home.actionen_HK
dc.relation.ispartofPLoS ONEen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subject.meshAnimals-
dc.subject.meshAntibodies, Viral - chemistry-
dc.subject.meshFemale-
dc.subject.meshGenetic Vectors-
dc.subject.meshVaccinia virus - genetics-
dc.titleA novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccinationen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1932-6203&volume=4&issue=1, article no. e4180&spage=&epage=&date=2009&atitle=A+novel+replication-competent+vaccinia+vector+MVTT+is+superior+to+MVA+for+inducing+high+levels+of+neutralizing+antibody+via+mucosal+vaccination-
dc.identifier.emailLiu, L: liuli71@hkucc.hku.hken_HK
dc.identifier.emailChen, Z: zchenai@hku.hken_HK
dc.identifier.authorityLiu, L=rp00268en_HK
dc.identifier.authorityChen, Z=rp00243en_HK
dc.description.naturepublished_or_final_versionen_US
dc.identifier.doi10.1371/journal.pone.0004180en_HK
dc.identifier.pmid19159014-
dc.identifier.pmcidPMC2613559-
dc.identifier.scopuseid_2-s2.0-58449100288en_HK
dc.identifier.hkuros163892en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-58449100288&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume4en_HK
dc.identifier.issue1en_HK
dc.identifier.isiWOS:000265479600001-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridHuang, X=22234542700en_HK
dc.identifier.scopusauthoridLu, B=50162127500en_HK
dc.identifier.scopusauthoridYu, W=50162901500en_HK
dc.identifier.scopusauthoridFang, Q=55248545600en_HK
dc.identifier.scopusauthoridLiu, L=35784425200en_HK
dc.identifier.scopusauthoridZhuang, K=6603626241en_HK
dc.identifier.scopusauthoridShen, T=24529121300en_HK
dc.identifier.scopusauthoridWang, H=8724886600en_HK
dc.identifier.scopusauthoridTian, P=36861331400en_HK
dc.identifier.scopusauthoridZhang, L=8783285300en_HK
dc.identifier.scopusauthoridChen, Z=35271180800en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats